Sino Biopharmaceutical Limited (SMZ1) - Net Assets
Based on the latest financial reports, Sino Biopharmaceutical Limited (SMZ1) has net assets worth €45.78 Billion EUR as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€74.89 Billion) and total liabilities (€29.12 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €45.78 Billion |
| % of Total Assets | 61.12% |
| Annual Growth Rate | 17.55% |
| 5-Year Change | 90.79% |
| 10-Year Change | 309.59% |
| Growth Volatility | 59.35 |
Sino Biopharmaceutical Limited - Net Assets Trend (2013–2024)
This chart illustrates how Sino Biopharmaceutical Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sino Biopharmaceutical Limited (2013–2024)
The table below shows the annual net assets of Sino Biopharmaceutical Limited from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €42.77 Billion | +12.06% |
| 2023-12-31 | €38.17 Billion | +0.60% |
| 2022-12-31 | €37.94 Billion | +0.57% |
| 2021-12-31 | €37.73 Billion | +68.29% |
| 2020-12-31 | €22.42 Billion | -44.35% |
| 2019-12-31 | €40.28 Billion | +7.28% |
| 2018-12-31 | €37.55 Billion | +197.75% |
| 2017-12-31 | €12.61 Billion | +17.98% |
| 2016-12-31 | €10.69 Billion | +2.36% |
| 2015-12-31 | €10.44 Billion | +18.42% |
| 2014-12-31 | €8.82 Billion | +22.05% |
| 2013-12-31 | €7.22 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sino Biopharmaceutical Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 584.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €25.28 Billion | 79.10% |
| Other Components | €6.68 Billion | 20.90% |
| Total Equity | €31.96 Billion | 100.00% |
Sino Biopharmaceutical Limited Competitors by Market Cap
The table below lists competitors of Sino Biopharmaceutical Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ALTEOGEN Inc
KQ:196170
|
$13.27 Billion |
|
Toll Brothers Inc
NYSE:TOL
|
$13.29 Billion |
|
Ovintiv Inc
NYSE:OVV
|
$13.30 Billion |
|
Evolution Mining Limited
F:WE7
|
$13.30 Billion |
|
The Siam Commercial Bank Public Company Limited
BK:SCB-R
|
$13.22 Billion |
|
CP ALL Public Company Limited
BK:CPALL
|
$13.20 Billion |
|
CNH Industrial N.V.
NYSE:CNH
|
$13.20 Billion |
|
CG Power and Industrial Solutions Limited
NSE:CGPOWER
|
$13.20 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sino Biopharmaceutical Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 30,474,469,000 to 31,960,789,000, a change of 1,486,320,000 (4.9%).
- Net income of 3,499,834,000 contributed positively to equity growth.
- Dividend payments of 1,846,381,000 reduced retained earnings.
- Share repurchases of 1,252,200,000 reduced equity.
- New share issuances of 150,674,000 increased equity.
- Other factors increased equity by 934,393,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €3.50 Billion | +10.95% |
| Dividends Paid | €1.85 Billion | -5.78% |
| Share Repurchases | €1.25 Billion | -3.92% |
| Share Issuances | €150.67 Million | +0.47% |
| Other Changes | €934.39 Million | +2.92% |
| Total Change | €- | 4.88% |
Book Value vs Market Value Analysis
This analysis compares Sino Biopharmaceutical Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.36x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.15x to 0.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.55 | €0.63 | x |
| 2018-12-31 | €1.54 | €0.63 | x |
| 2019-12-31 | €1.65 | €0.63 | x |
| 2020-12-31 | €0.89 | €0.63 | x |
| 2021-12-31 | €1.61 | €0.63 | x |
| 2022-12-31 | €1.58 | €0.63 | x |
| 2023-12-31 | €1.62 | €0.63 | x |
| 2024-12-31 | €1.76 | €0.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sino Biopharmaceutical Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.95%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.12%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 2.05x
- Recent ROE (10.95%) is below the historical average (20.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 18.89% | 10.47% | 0.99x | 1.82x | €488.06 Million |
| 2014 | 22.89% | 12.22% | 0.87x | 2.14x | €852.14 Million |
| 2015 | 22.93% | 12.22% | 0.88x | 2.13x | €1.00 Billion |
| 2016 | 21.53% | 12.09% | 0.77x | 2.31x | €917.61 Million |
| 2017 | 23.57% | 14.65% | 0.71x | 2.27x | €1.25 Billion |
| 2018 | 30.97% | 43.31% | 0.42x | 1.70x | €6.13 Billion |
| 2019 | 8.70% | 11.17% | 0.42x | 1.87x | €-404.37 Million |
| 2020 | 16.55% | 11.72% | 0.50x | 2.82x | €1.10 Billion |
| 2021 | 48.23% | 54.38% | 0.44x | 2.00x | €11.58 Billion |
| 2022 | 8.55% | 9.77% | 0.41x | 2.15x | €-431.13 Million |
| 2023 | 7.65% | 8.90% | 0.41x | 2.09x | €-715.51 Million |
| 2024 | 10.95% | 12.12% | 0.44x | 2.05x | €303.76 Million |
Industry Comparison
This section compares Sino Biopharmaceutical Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $-83,465,177
- Average return on equity (ROE) among peers: -248.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sino Biopharmaceutical Limited (SMZ1) | €45.78 Billion | 18.89% | 0.64x | $13.26 Billion |
| 09R (09R) | $-2.13 Million | 0.00% | 0.00x | $24.67 Million |
| PreveCeutical Medical Inc (18H) | $-5.78 Million | 0.00% | 0.00x | $3.34 Million |
| IDORSIA AG (19T) | $-1.14 Billion | 0.00% | 0.00x | $978.02 Million |
| ONCOARENDI THERAP ZY-01 (1B1) | $126.45 Million | -12.07% | 0.09x | $24.94 Million |
| Flerie AB (publ) (1NP1) | $333.96 Million | -30.04% | 0.05x | $231.62 Million |
| NUFORMIX PLC LS -001 (1RT) | $5.69 Million | -22.04% | 0.06x | $1.53 Million |
| 1S90 (1S90) | $10.78 Million | -2319.92% | 31.35x | $70.17 Million |
| Strategic Partners A/S (1TB0) | $19.25 Million | -1.55% | 0.22x | $3.69 Million |
| Entheon Biomedical Corp. (1XU) | $324.03K | -99.99% | 0.09x | $502.28K |
| 25K0 (25K0) | $-186.02 Million | 0.00% | 0.00x | $125.12 Million |
About Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injecti… Read more